Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 4 von insgesamt 4
- Rekrutierung läuft
A PHASE I, FIRST IN HUMAN, TWO PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT-INHIBITOR IN SUBJECTS WITH ADVANCED STAGE, RELAPSED/REFRACTORY SOLID TUMORS
Molekulare Marker - Rekrutierung läuft
AN OPEN-LABEL, MULTICENTER, PHASE I/IB TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
Molekulare Marker - Rekrutierung läuftA PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY,PHARMACOKINETICS, AND ACTIVITY OF BELVARAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH EITHER COBIMETINIB OR COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH NRAS-MUTANT ADVANCED MELANOMA WHO HAVE RECEIVED ANTI PD-1/PD-L1 THERAPYIndikationenMolekulare Marker
- Rekrutierung läuftA Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma